May 2025:

In April 2025, PatientView released the 14th edition of the Corporate Reputation of Pharma report. This year, the number of pharmaceutical companies in the analyses increased to 46, including eleven new biotechnology companies – at the request of patient groups.

This broader, more representative scope is reflected in this year’s rankings. Some big pharma companies have dropped slightly compared to previous years, while a number of newer, smaller biotech companies have performed well.

The new additions are: Alnylam Pharmaceuticals, Angelini Pharma, Crinetics Pharmaceuticals, Esteve Healthcare, Exelixis, Jazz Pharmaceuticals, Incyte, Recordati, Regeneron Pharmaceuticals, Sobi and Viatris.

Why were these pharmaceutical companies selected?

Biotech and biopharma pharmaceutical companies are making notable strides in research and development and have increasingly captured the attention of patient groups. Many of the respondent patient groups specifically requested that we include them in the survey.

As the Corporate Reputation of Pharma survey is built around patient-group perspectives, it is essential that the companies they are actively engaging with are reflected. Including these new biotechs offers a more accurate and up-to-date view of the healthcare landscape.

What does this mean for the rankings of large pharma companies?

With the expanded list, large pharma companies now have the opportunity to benchmark themselves not only against peers but also against smaller innovators. This allows for richer comparisons and insight into how they can strengthen their relationships with patient groups.

The report continues to include the full scores and rankings of 15 ‘big pharma’ pharmaceutical companies that have long been part of the survey, making it possible to track historical performance year-on-year, while also exploring how the competitive landscape is evolving.

Why have some of the newly added biotech companies performed so well?

From patient group commentaries, PatientView have identified several reasons why a number of these smaller biotechs have performed so well in the 2024/25 Corporate Reputation of Pharma report.

Many patient groups describe these companies as more agile and less burdened by the complexity and bureaucracy often associated with larger pharmaceutical companies. These biotechs tend to make decisions fast, are easy to collaborate with, and maintain more direct relationships with patient organisations. Importantly, patient groups also noted that with biotechs, they feel less sidelined and have better access to company decision-makers and leadership teams.

Some of the new biotech companies have designed their business around patient involvement from the outset, and patient groups view them as inherently more patient-centred. Due to their small size, they are also valued for focusing on specialised therapy areas to address unmet needs in rarer diseases and conditions. In some cases, biotech companies are seen by patient groups to be leading innovation in the industry and putting their own disease centre-stage rather than an add-on in a large portfolio.

What can biotech and pharma companies do to improve their corporate reputation among their patient-group partners?

Each year, PatientView collects detailed commentaries from patient groups about how pharmaceutical companies can improve their relationships and reputation with them.

For the 2023/24 survey, these commentaries have been aggregated, classified and thematically analysed to create the first in a new series of Moving Forward dashboards.

Moving Forward is designed to help you translate insight into impact, so you can respond to what matters most to patient communities you work with and strengthen your company’s reputation.

With the Moving Forward dashboard, pharmaceutical companies can:

  • Explore patient group priorities by country and disease area, mapped across the 10 indicators of corporate reputation.
  • You can search the database for the top priorities of patient groups in your therapy areas and market
  • Drill down to the level of detail you need, including specific quotes in multiple languages.
  • Build bespoke datasets across any therapy and geographical region
  • Identify actionable steps that need to be taken to improve company performance for each patient group priority, as told by the patient groups themselves.

To conclude ‘Broadening representation – why new companies entered PatientView’s 2024/25 Corporate Reputation of Pharma rankings‘, the expansion of the Corporate Reputation of Pharma report reflects a changing healthcare landscape. One where patient groups are engaging with a broader mix of pharmaceutical companies, from big pharma to agile biotech innovators.

By listening closely to patient group feedback, PatientView aims to offer a clearer picture of what a good corporate reputation looks like in practice and how companies can improve theirs.

Whether you are a new entrant or an established pharma company, the insights in this year’s report and the new Moving Forward dashboard provide a roadmap for building stronger, more trusted relationships with patient groups.